MBIOHealthcare · BiotechnologyMBIO Stock Forecast: Mustang Bio, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 13 of 100 as at 21 Aug 2026 — in the weakest quartile.
MBIO stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Mustang Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (97): Smaller than most of the companies we track.
Momentum (4): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
MBIO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MBIO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 May 2024 | HC Wainwright & Co. | Reiterates | Buy | $2.00 |
| 13 May 2024 | HC Wainwright & Co. | Maintains | Buy | $25 → $2.00 |
| 24 Aug 2023 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 16 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2023 | BTIG | Maintains | Buy | — |
| 15 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 June 2023 | BTIG | Maintains | Buy | — |
| 16 June 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Mar 2023 | HC Wainwright & Co. | Reiterates | Buy | $7.00 |
| 16 Nov 2022 | BTIG | Maintains | Buy | $8.00 → $4.00 |
| 24 Jan 2022 | B. Riley Securities | Maintains | Buy | $13 → $6.00 |
| 18 May 2021 | BTIG | Initiates | Buy | — |
| 2 Oct 2020 | B. Riley FBR | Initiates | Buy | — |
| 2 Oct 2020 | B. Riley Securities | Initiates | Buy | — |
| 12 May 2020 | Oppenheimer | Maintains | Outperform | $15 → $13 |
| 13 Aug 2019 | H.C. Wainwright | Initiates | Buy | — |
| 13 Aug 2019 | HC Wainwright & Co. | Initiates | Buy | — |
| 21 June 2019 | Cantor Fitzgerald | Initiates | Overweight | — |
| 21 Dec 2017 | Oppenheimer | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MBIO appears on the weeks it earns a place.
MBIO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Mustang Bio, Inc. (MBIO) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.6×
- Price / sales
- —
- Price / book
- 0.6×
- EV / EBITDA
- 3.1×
Cheaper than 71% of US stocks
Cheaper than 84% of US stocks
Cheaper than 56% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- −58.1%
- Return on assets
- −15.4%
- Dividend yield
- —
Higher than 19% of US stocks
Higher than 22% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
MBIO vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Mustang Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about MBIO stock
Is MBIO stock a buy right now?
Of the 1 analysts covering Mustang Bio, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Mustang Bio, Inc. 13 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MBIO?
As at 21 Aug 2026, Mustang Bio, Inc. ranks 13 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).
What is the MBIO stock forecast for 2030?
No analyst covering Mustang Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MBIO are extrapolating price history, which says nothing about the business.
How has MBIO stock performed over the past year?
Mustang Bio, Inc. returned -65.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Mustang Bio, Inc. do?
Mustang Bio Inc. is a biotechnology company specializing in the development and commercialization of innovative and targeted therapies in the field of oncology.
About Mustang Bio, Inc.
Mustang Bio Inc. is a biotechnology company specializing in the development and commercialization of innovative and targeted therapies in the field of oncology. Its primary function is to advance the treatment of various cancers and genetic diseases through proprietary cell and gene therapies. Mustang Bio focuses on leveraging its scientific expertise to create therapies that specifically target cancer cells, hence improving treatment outcomes while minimizing side effects. The company’s research and development efforts have led to a robust pipeline, particularly concentrating on CAR-T cell therapies and gene therapies. Operating within the dynamic and rapidly evolving biotechnology industry, Mustang Bio plays a crucial role in addressing unmet medical needs, bringing transformative therapies from the laboratory to the clinic. By collaborating with academic institutions and a network of research partners, Mustang Bio enhances its capabilities in developing next-generation therapies. The company's contributions to the biotech sector underline its importance in bringing cutting-edge medical solutions to market, potentially transforming patient care and offering new hope in the treatment of life-threatening diseases.
CEO Dr. Manuel Litchman M.D. · 4 employees · United States · https://www.mustangbio.com